Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT

• Published in: Journal of the American College of Cardiology 2021-10, Vol.78 (15), p.1525-1537
• Main Authors: Gaba, Prakriti, Bhatt, Deepak L., Giugliano, Robert P., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Juliano, Rebecca A., Jiao, Lixia, Doyle, Ralph T., Granowitz, Craig, Tardif, Jean-Claude, Ballantyne, Christie M., Pinto, Duane S., Budoff, Matthew J., Gibson, C. Michael
• Format: Article
• Language: English
• Subjects: Aged; Angina, Unstable - epidemiology; central adjudication; clinical trials; Eicosapentaenoic Acid - analogs & derivatives; Eicosapentaenoic Acid - therapeutic use; Endpoint Determination; Female; Humans; Hypertriglyceridemia - drug therapy; icosapent ethyl; investigator-reported endpoints; Lipid Regulating Agents - therapeutic use; Male; Myocardial Infarction - epidemiology; Myocardial Revascularization - statistics & numerical data; Stroke - epidemiology
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2021.08.009

REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial) randomized statin-treated patients with elevated triglycerides to icosapent ethyl (IPE) or placebo. There was a significant reduction in adjudicated events, including the primary endpoint (cardiovascular [CV] death, myocardial infarction [MI], stroke, coronary revascularization, unstable angina requiring hospitalization) and key secondary endpoint (CV death, MI, stroke) with IPE. The purpose of this study was to determine the effects of IPE on investigator-reported events. Potential endpoints were collected by blinded site investigators and subsequently adjudicated by a blinded Clinical Endpoint Committee (CEC) according to a prespecified charter. Investigator-reported events were compared with adjudicated events for concordance. There was a high degree of concordance between investigator-reported and adjudicated endpoints. The simple Kappa statistic between CEC-adjudicated vs site-reported events for the primary endpoint was 0.89 and for the key secondary endpoint was 0.90. Based on investigator-reported events in 8,179 randomized patients, IPE significantly reduced the rate of the primary endpoint (19.1% vs 24.6%; HR: 0.74 [95% CI: 0.67-0.81]; P < 0.0001) and the key secondary endpoint (10.5% vs 13.6%; HR: 0.75 [95% CI: 0.66-0.85]; P < 0.0001). Among adjudicated events, IPE similarly reduced the rate of the primary and key secondary endpoints. IPE led to consistent, significant reductions in CV events, including MI and coronary revascularization, as determined by independent, blinded CEC adjudication as well as by blinded investigator-reported assessment. These results highlight the robust evidence for the substantial CV benefits of IPE seen in REDUCE-IT and further raise the question of whether adjudication of CV outcome trial endpoints is routinely required in blinded, placebo-controlled trials. (Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT [Reduction of Cardiovascular Events With EPA - Intervention Trial]; NCT01492361) [Display omitted]